238 related articles for article (PubMed ID: 3925573)
1. [Response to DDAVP in von Willebrand disease type II C].
Batllé Fonrodona J; López Fernández MF; Martín González R; Fernández Villamor A; López Borrasca A; Lasierra Cirujeda J
Sangre (Barc); 1985; 30(2):181-4. PubMed ID: 3925573
[No Abstract] [Full Text] [Related]
2. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
Santiago-Borrero PJ; Casanova R
Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
[TBL] [Abstract][Full Text] [Related]
3. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
Warrier AI; Lusher JM
J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
[TBL] [Abstract][Full Text] [Related]
4. [The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on blood coagulation in patients with hemophilia A and in healthy men].
Blättler W; Jacky E; Müller M; Graf M
Schweiz Med Wochenschr; 1979 Sep; 109(37):1367-8. PubMed ID: 314661
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of D-arginine vasopressin in von Willebrand's disease.
Bala L; Boggio L; Green D
Curr Hematol Rep; 2005 Jan; 4(1):1-2. PubMed ID: 15610653
[No Abstract] [Full Text] [Related]
6. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.
Ruggeri ZM; Mannucci PM; Lombardi R; Federici AB; Zimmerman TS
Blood; 1982 Jun; 59(6):1272-8. PubMed ID: 6805532
[TBL] [Abstract][Full Text] [Related]
7. [DDAVP: alternative therapy in moderate pathology of Factor VIII/von Willebrand].
Vicente V; Alberca I; Moraleda JM; López Borrasca A
Sangre (Barc); 1983; 28(4):531-2. PubMed ID: 6606856
[No Abstract] [Full Text] [Related]
8. DDAVP in haemophilia and von Willebrand's disease.
Lancet; 1983 Oct; 2(8353):774-5. PubMed ID: 6137606
[No Abstract] [Full Text] [Related]
9. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
10. [Hemostatic effect of deamino-8-D-arginine vasopressin (DDAVP) in hemophilia A and von Willebrand's disease].
Fukui H; Takase T
Rinsho Ketsueki; 1985 Jul; 26(7):1069-79. PubMed ID: 3932720
[No Abstract] [Full Text] [Related]
11. No influence of blood group on the responsiveness to desmopressin in type I "platelet normal" von Willebrand's disease.
Castaman G; Rodeghiero F
Thromb Haemost; 1995 Mar; 73(3):551-2. PubMed ID: 7667843
[No Abstract] [Full Text] [Related]
12. [Clinical application of new synthetic vasopressin 1-deamino-8-D-arginine vasopressin (DDAVP): hemostatic control of von Willebrand's disease (author's transl)].
Kobayashi I; Takahashi H; Sanada M; Takahashi K; Hattori A; Ito M; Sakuragawa N; Shibata A; Shinada S; Tsukada T
Rinsho Ketsueki; 1979 Apr; 20(4):364-71. PubMed ID: 312954
[No Abstract] [Full Text] [Related]
13. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
14. Mild forms of von Willebrand disease: diagnosis and management.
Federici AB
Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of blood coagulation disorders with the vasopressin derivative DDAVP (Minirin)].
Köhler M; Hellstern P; Vief B; Wenzel E
ZFA (Stuttgart); 1981 May; 57(15):1132-5. PubMed ID: 6973250
[No Abstract] [Full Text] [Related]
16. [Multimeric composition of factor VIII-related protein following DDAVP infusion in normal subjects and patients with hemophilia A and von Willebrand's disease].
Takase T; Nishino M; Yasui M; Shima M; Yoshikawa N; Fukui H
Nihon Ketsueki Gakkai Zasshi; 1985 Nov; 48(7):1571-8. PubMed ID: 3937410
[No Abstract] [Full Text] [Related]
17. Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand's disease. A study on 43 patients.
Mariana G; Ciavarella N; Mazzucconi MG; Antoncecchi S; Solinas S; Ranieri P; Pettini P; Agrestini F; Mandelli F
Clin Lab Haematol; 1984; 6(3):229-38. PubMed ID: 6440729
[TBL] [Abstract][Full Text] [Related]
18. Update on the management of von Willebrand disease.
Federici AB
Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438
[No Abstract] [Full Text] [Related]
19. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
20. DDAVP in von Willebrand's disease: repeated administration and the behaviour of the bleeding time.
Theiss W; Schmidt G
Thromb Res; 1978 Dec; 13(6):1119-23. PubMed ID: 311959
[No Abstract] [Full Text] [Related]
[Next] [New Search]
